이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aceso Life Science Group 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	7.7yrs
이사회 평균 재임 기간	11.9yrs

최근 관리 업데이트

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

CEO

Aceso Life Science Group 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Chi Tak Fok	CFO & Executive Director	13.6yrs	HK$6.10m	0.82% HK$ 6.4m
Shao Yu Li	Senior Consultant	8.8yrs	HK$13.20m	57.52% HK$ 445.8m
Zhiliang Ou	Executive Director	no data	HK$600.00k	0.0099% HK$ 77.0k
Xiaodong Liu	Chief Operating Officer	5.8yrs	데이터 없음	데이터 없음
Chun Law	Group Financial Controller	7.7yrs	데이터 없음	데이터 없음
Chun Pong Siu	Company Secretary	1.9yrs	데이터 없음	데이터 없음

7.7yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: 474 의 관리팀은 노련하고 경험 (평균 재직 기간 7.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chi Tak Fok	CFO & Executive Director	10.8yrs	HK$6.10m	0.82% HK$ 6.4m
Zhiliang Ou	Executive Director	12.1yrs	HK$600.00k	0.0099% HK$ 77.0k
Kwan Sing Lam	Independent Non-Executive Director	11.9yrs	HK$200.00k	0.0099% HK$ 77.0k
Ming Sun Chan	Independent Non-Executive Director	12.3yrs	HK$200.00k	0.0099% HK$ 77.0k
Yiu Tong Mak	Independent Non-Executive Director	3yrs	HK$200.00k	데이터 없음

11.9yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 474 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.8 년).

Aceso Life Science Group 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Aceso Life Science Group Limited Announces Change of Company Secretary

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Senior Consultant recently bought HK$18m worth of stock

Recent updates

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

CEO

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령